Psychedelic Medicine

Download or read book Psychedelic Medicine written by Richard Louis Miller and published by Simon and Schuster. This book was released on 2017-11-21 with total page 316 pages. Available in PDF, EPUB and Kindle. Book excerpt: Explores the potential of psychedelics as medicine and the intersections of politics, science, and psychedelics • Explores the tumultuous history of psychedelic research, the efforts to restore psychedelic therapies, and the links between psychiatric drugs and mental illness • Offers non-technical summaries of the most recent, double-blind, placebo-controlled studies with MDMA, psilocybin, LSD, and ayahuasca • Includes the work of Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker Embracing the revival of psychedelic research and the discovery of new therapeutic uses, clinical psychologist Dr. Richard Louis Miller discusses what is happening today in psychedelic medicine--and what will happen in the future--with top researchers and thinkers in this field, including Rick Doblin, Stanislav Grof, James Fadiman, Julie Holland, Dennis McKenna, David Nichols, Charles Grob, Phil Wolfson, Michael and Annie Mithoefer, Roland Griffiths, Katherine MacLean, and Robert Whitaker. Dr. Miller and his contributors cover the tumultuous history of early psychedelic research brought to a halt 50 years ago by the U.S. government as well as offering non-technical summaries of the most recent studies with MDMA, psilocybin, LSD, and ayahuasca. They explore the biochemistry of consciousness and the use of psychedelics for self-discovery and healing. They discuss the use of psilocybin for releasing fear in the terminally ill and the potential for MDMA-assisted psychotherapy in the treatment of PTSD. They examine Dr. Charles Grob’s research on the indigenous use and therapeutic properties of ayahuasca and Dr. Gabor Mate’s attempt to transport this plant medicine to a clinical setting with the help of Canada’s Department of National Health. Dr. Miller and his contributors explore the ongoing efforts to restore psychedelic therapies to the health field, the growing threat of overmedication by the pharmaceutical industry, and the links between psychiatric drugs and mental illness. They also discuss the newly shifting political climate and the push for new research, offering hope for an end to the War on Drugs and a potential renaissance of research into psychedelic medicines around the world.

Download or read book Handbook of Medical Hallucinogens written by Charles S. Grob and published by Guilford Publications. This book was released on 2023-01-13 with total page 602 pages. Available in PDF, EPUB and Kindle. Book excerpt: This handbook reviews promising applications of psychedelics in treatment of such challenging psychiatric problems as posttraumatic stress disorder, major depression, substance use disorders, and end-of-life anxiety. Experts from multiple disciplines synthesize current knowledge on psilocybin, MDMA, ketamine, and other medical hallucinogens. The volume comprehensively examines these substances' neurobiological mechanisms, clinical effects, therapeutic potential, risks, and anthropological and historical contexts. Coverage ranges from basic science to practical clinical considerations, including patient screening and selection, dosages and routes of administration, how psychedelic-assisted sessions are structured and conducted, and management of adverse reactions.

Download or read book Advances in Psychedelic Medicine written by Michael J. Winkelman and published by Bloomsbury Publishing USA. This book was released on 2019-03-22 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psychological, physiological, and social problems. More than a decade ago, the U.S. government lifted its ban on all testing of psychedelic substances. Winkelman and Sessa now provide updated scientific research and applications of these substances, now moving into approved categories of medicine. The text is an up-to-date assessment of the latest advances in the field of psychedelic medicine, covering the use of LSD, psilocybin, MDMA, ayahuasca, and other substances to augment psychotherapies for a range of disorders. It discusses medical and psychiatric concerns, clinical efficacy and safety, ethical considerations, and neuroscience findings regarding the psychedelic compounds. Topics covered include an overview of psychiatric applications of psychedelics; treatments for addictions and depressive disorders; effects of psychedelics on inflammation and neuroplasticity; evidence for clinical applications of DMT, ayahuasca, and cannabidiol; psychedelic treatment of sociopathic disorders; microdosing psychedelics; training psychedelic therapists; and community-based harm reduction approaches to managing psychedelic crises.

Download or read book Psychedelic Drugs Reconsidered written by Lester Grinspoon and published by Bookworld Services. This book was released on 1997 with total page 385 pages. Available in PDF, EPUB and Kindle. Book excerpt: First published in 1979, Psychedelic Drugs Reconsidered is regarded by many as the most comprehensive, accurate, and accessible analysis of psychedelic drugs for the general reader. It records the extensive history of scientific research on, and societal experience with, psychedelic drugs. The Lindesmith Center reprint edition features a new introduction by the authors on recent developments in psychedelic research, as well as a preface by Dr. Ethan Nadelmann, director of the Lindesmith center.

Download or read book Behavioral Neurobiology of Psychedelic Drugs written by Adam L. Halberstadt and published by Springer. This book was released on 2018-03-27 with total page 434 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.

Download or read book The Trials of Psychedelic Therapy written by Matthew Oram and published by JHU Press. This book was released on 2018-10-01 with total page 430 pages. Available in PDF, EPUB and Kindle. Book excerpt: The rise—and fall—of research into the therapeutic potential of LSD. After LSD arrived in the United States in 1949, the drug's therapeutic promise quickly captured the interests of psychiatrists. In the decade that followed, modern psychopharmacology was born and research into the drug's perceptual and psychological effects boomed. By the early 1960s, psychiatrists focused on a particularly promising treatment known as psychedelic therapy: a single, carefully guided, high-dose LSD session coupled with brief but intensive psychotherapy. Researchers reported an astounding 50 percent success rate in treating chronic alcoholism, as well as substantial improvement in patients suffering from a range of other disorders. Yet despite this success, LSD officially remained an experimental drug only. Research into its effects, psychological and otherwise, dwindled before coming to a close in the 1970s. In The Trials of Psychedelic Therapy, Matthew Oram traces the early promise and eventual demise of LSD psychotherapy in the United States. While the common perception is that LSD's prohibition terminated legitimate research, Oram draws on files from the Food and Drug Administration and the personal papers of LSD researchers to reveal that the most significant issue was not the drug's illegality, but the persistent question of its efficacy. The landmark Kefauver-Harris Drug Amendments of 1962 installed strict standards for efficacy evaluation, which LSD researchers struggled to meet due to the unorthodox nature of their treatment. Exploring the complex interactions between clinical science, regulation, and therapeutics in American medicine, The Trials of Psychedelic Therapy explains how an age of empirical research and limited government oversight gave way to sophisticated controlled clinical trials and complex federal regulations. Analyzing the debates around how to understand and evaluate treatment efficacy, this book will appeal to anyone with an interest in LSD and psychedelics, as well as mental health professionals, regulators, and scholars of the history of psychiatry, psychotherapy, drug regulation, and pharmaceutical research and development.

Download or read book Psychedelic Psychiatry written by Erika Dyck and published by JHU Press. This book was released on 2008-09-15 with total page 217 pages. Available in PDF, EPUB and Kindle. Book excerpt: LSD's short but colorful history in North America carries with it the distinct cachet of counterculture and government experimentation. The truth about this mind-altering chemical cocktail is far more complex—and less controversial—than generally believed. Psychedelic Psychiatry is the tale of medical researchers working to understand LSD’s therapeutic properties just as escalating anxieties about drug abuse in modern society laid the groundwork for the end of experimentation at the edge of psychopharmacology. Historian Erika Dyck deftly recasts our understanding of LSD to show it as an experimental substance, a medical treatment, and a tool for exploring psychotic perspectives—as well as a recreational drug. She recounts the inside story of the early days of LSD research in small-town, prairie Canada, when Humphry Osmond and Abram Hoffer claimed incredible advances in treating alcoholism, understanding schizophrenia and other psychoses, and achieving empathy with their patients. In relating the drug’s short, strange trip, Dyck explains how concerns about countercultural trends led to the criminalization of LSD and other so-called psychedelic drugs—concordantly opening the way for an explosion in legal prescription pharmaceuticals—and points to the recent re-emergence of sanctioned psychotropic research among psychiatric practitioners. This challenge to the prevailing wisdom behind drug regulation and addiction therapy provides a historical corrective to our perception of LSD’s medical efficacy.